Study 117 found that lenvatinib plus the anti-PD-1 monoclonal antibody nivolumab resulted in an objective response rate of 66.7% and a clinical benefit rate of 70.8% in patients with advanced HCC (Kudo et al., 2020). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.